Gencurix Inc. (229000.KQ)

KRW 1446.0

(-0.69%)

EBITDA Summary of Gencurix Inc.

Gencurix Inc.'s latest annual EBITDA in 2023 was -18.09 Billion KRW , down -4.47% from previous year.
Gencurix Inc.'s latest quarterly EBITDA in 2024 Q2 was -2.62 Billion KRW , down -28.81% from previous quarter.
Gencurix Inc. reported an annual EBITDA of -23.94 Billion KRW in 2022, up 14.58% from previous year.
Gencurix Inc. reported an annual EBITDA of -34.26 Billion KRW in 2021, down -34.48% from previous year.
Gencurix Inc. reported a quarterly EBITDA of -2.62 Billion KRW for 2024 Q2, down -28.81% from previous quarter.
Gencurix Inc. reported a quarterly EBITDA of -2.81 Billion KRW for 2023 Q1, up 7.98% from previous quarter.

Annual EBITDA Chart of Gencurix Inc. (2023 - 2015)

Historical Annual EBITDA of Gencurix Inc. (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	-18.09 Billion KRW	-4.47%
2022	-23.94 Billion KRW	14.58%
2021	-34.26 Billion KRW	-34.48%
2020	-9.15 Billion KRW	-60.84%
2019	-8.25 Billion KRW	-11.04%
2018	-5.11 Billion KRW	11.59%
2017	-6.27 Billion KRW	22.98%
2016	-7.48 Billion KRW	-123.05%
2015	-3.25 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-2.67 Billion KRW	16.6%
2024 Q2	-2.62 Billion KRW	-28.81%
2023 Q1	-2.81 Billion KRW	7.98%
2023 Q3	-2.2 Billion KRW	31.31%
2023 Q4	-2.75 Billion KRW	-24.56%
2023 Q2	-3.21 Billion KRW	-14.3%
2023 FY	- KRW	-4.47%
2022 Q2	-2.99 Billion KRW	-48.74%
2022 FY	- KRW	14.58%
2022 Q4	-3.05 Billion KRW	-24.47%
2022 Q3	-2.45 Billion KRW	17.95%
2022 Q1	-2.01 Billion KRW	63.82%
2021 FY	- KRW	-34.48%
2021 Q2	-2.83 Billion KRW	-52.82%
2021 Q3	-2.05 Billion KRW	27.44%
2021 Q4	-5.56 Billion KRW	-170.09%
2021 Q1	-1.85 Billion KRW	58.49%
2020 Q1	-1.48 Billion KRW	22.31%
2020 FY	- KRW	-60.84%
2020 Q4	-4.47 Billion KRW	-173.41%
2020 Q3	-1.63 Billion KRW	-4.85%
2020 Q2	-1.56 Billion KRW	-5.12%
2019 FY	- KRW	-11.04%
2019 Q4	-1.91 Billion KRW	-39.38%
2019 Q3	-1.37 Billion KRW	0.0%
2018 FY	- KRW	11.59%
2017 FY	- KRW	22.98%
2016 FY	- KRW	-123.05%
2015 FY	- KRW	0.0%

Peer EBITDA Comparison of Gencurix Inc.

Name	EBITDA	EBITDA Difference
Osang Healthcare Co.,Ltd	157.89 Billion KRW	111.459%
InBody Co.,Ltd	44.25 Billion KRW	140.88%
Curexo Inc.	-2.75 Billion KRW	-557.05%
Seegene, Inc.	35.65 Billion KRW	150.743%
i-SENS, Inc.	24.14 Billion KRW	174.935%
Ray Co., Ltd.	7.62 Billion KRW	337.308%
Sugentech Inc.	-12.13 Billion KRW	-49.14%
L&C Bio Co., Ltd	13.4 Billion KRW	234.998%